SEC Form 4
Candel Therapeutics, Inc. (CADL) insider trading
In the 12 months to Oct 26, 2026, 3 CADL insiders reported open-market sales of $3.6M across 4 filings; one director bought $3.0M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $3.6M
- 4 filings · 3 insiders
- Open-market purchases
- $3.0M
- 1 filing · Paul B. Manning, Director
- Pre-arranged sales (10b5-1)
- 4 of 4
- All $3.6M sold was pre-arranged
Who traded CADL, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
CADL daily close from Oct 27, 2025 to Oct 26, 2026, between $4.42 and $13.75, last $7.86. 4 sale and 1 purchase filings by 4 insiders, marked at their filing dates. Paul Peter Tak, Chief Executive Officer: sold $3.2M across 1 filing, first filed Sep 11, 2026, last Sep 11, 2026. Paul B. Manning, Director: bought $3.0M across 1 filing, first filed Feb 26, 2026, last Feb 26, 2026. Francesca Barone, Chief Scientific Officer: sold $235.8K across 1 filing, first filed Jul 1, 2026, last Jul 1, 2026. Seshu Tyagarajan, Chief Technology Officer: sold $154.2K across 2 filings, first filed Jul 1, 2026, last Aug 19, 2026.
Largest mark · tap a row for others
Paul Peter Tak · Chief Executive Officer
Sale $3,160,783
280,245 shares at $11.28 avg
Filed Sep 11, 2026 · traded Sep 10
Pre-arranged (10b5-1) · close on filing date $10.55
Paul Peter Tak · Chief Executive Officer
Chief Executive Officer
$3.2M soldPaul B. Manning · Director
Director
$3.0M boughtFrancesca Barone · Chief Scientific Officer
Chief Scientific Officer
$235.8K soldSeshu Tyagarajan · Chief Technology Officer
Chief Technology Officer
$154.2K soldOpen-market trades
5 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Paul Peter Tak | Chief Executive Officer | $3.2M | — | 1 | 100% of sales | |
| Paul B. Manning | Director | — | $3.0M | 1 | — | |
| Francesca Barone | Chief Scientific Officer | $235.8K | — | 1 | 100% of sales | |
| Seshu Tyagarajan | Chief Technology Officer | $154.2K | — | 2 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Paul Peter Tak Chief Executive Officer | SalePre-arranged (10b5-1) | 280,245 | $11.28 | $3.2M | 113,321 | |
traded | Seshu Tyagarajan Chief Technology Officer | SalePre-arranged (10b5-1) | 7,000 | $12.00 | $84.0K | 76,865 | |
traded | Francesca Barone Chief Scientific Officer | SalePre-arranged (10b5-1) | 23,447 | $10.06 | $235.8K | 77,362 | |
traded | Seshu Tyagarajan Chief Technology Officer | SalePre-arranged (10b5-1) | 7,000 | $10.02 | $70.2K | 83,865 | |
traded | Paul B. Manning Director | Purchase | 550,458 | $5.45 | $3.0M | 2,763,527 |
GET /stocks/filings/vX/form-4?tickers=CADL&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"CADL"
],
"issuer_cik": "0001841387",
"owner_cik": "0001873905",
"accession_number": "0001873905-26-000002",
"form_type": "4",
"filing_date": "2026-09-11",
"period_of_report": "2026-09-10",
"issuer_name": "Candel Therapeutics, Inc.",
"issuer_trading_symbol": "CADL",
"owner_name": "Tak Paul Peter",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Executive Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-10",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 220866,
"transaction_price_per_share": 11.4997,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 172700,
"transaction_value": 2539892.7402000003,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026."
},
{
"id": "F2",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.20 to $12.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein."
}
]
},
{
"tickers": [
"CADL"
],
"issuer_cik": "0001841387",
"owner_cik": "0001873905",
"accession_number": "0001873905-26-000002",
"form_type": "4",
"filing_date": "2026-09-11",
"period_of_report": "2026-09-10",
"issuer_name": "Candel Therapeutics, Inc.",
"issuer_trading_symbol": "CADL",
"owner_name": "Tak Paul Peter",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Executive Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-11",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 59379,
"transaction_price_per_share": 10.4564,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 113321,
"transaction_value": 620890.5756,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026."
},
{
"id": "F3",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $11.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 herein."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 1 record
- Option exercises1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Candel Therapeutics, Inc.'s CEO sold stock?
Yes. Paul Peter Tak (CEO) sold 280,245 shares ($3.2M) in Sep 2026, all under a pre-arranged 10b5-1 plan.
How current is CADL’s insider data?
These are CADL Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track CADL insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for CADL every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.